Stress ulcer prophylaxis is given commonly to patients in the ICU. However, the choice of which type or drug to use for this purpose or whether widespread use of ulcer prophylaxis is justified is debated. This talk will review current evidence in relation to stress ulcer prophylaxis in the ICU focusing on the recently published PEPTIC trial.
By the end of this lecture, the attendee will be able to:
- Understand the risks and benefits associated with the use of proton pump inhibitors for stress ulcer prophylaxis in the ICU.
- Describe the design and key findings of the PEPTIC trial.
- Develop a practical understanding of when to use stress prophylaxis based on available evidence.
- List key patient subgroups where data suggest that using proton pump inhibitors for stress ulcer prophylaxis may increase mortality risk.
This lecture is equal to 1 CE Contact Hour, 1 CPD Point, and 1 AMA PRA Category 1 Credit™
Additional CME Info
Release Date: February 1, 2020, Termination Date: January 31, 2023
Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of EB Medicine and Continulus. EB Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: EB Medicine designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit™ per lecture. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial Support: This activity received no commercial support.
Earning Credit: In order to earn CME credit, the participant must take the pre-test, listen to the lecture, take the CME post-test, and complete the post-test evaluation.
Duration 1 hour(s).
Dr. Paul Young
Dr. Paul Young an intensive care specialist and the co-clinical leader at Wellington Hospital ICU. He is a key member of the highly successful Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG) and leading member of the New Zealand ICU research community. His principal research interest is in the design and conduct of large-scale randomised controlled trials. Since he began working as an intensive care specialist at Wellington Hospital in 2010 more than 3,000 intensive care patients have been enrolled in clinical trials in the ICU.
Dr. Young is Associate Editor for Critical Care and Resuscitation (the highest impact journal in the field of Intensive Care Medicine outside the US and Europe). He has more than 150 publications, including six in the New England Journal of Medicine and is involved in collaborations with researchers from Australia, Canada, Europe, the USA, and the UK.
CME Faculty Disclosure: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. In compliance with all ACCME Essentials, Standards, and Guidelines, all faculty for this CME activity were asked to complete a full disclosure statement. The speaker did not report any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) discussed in this educational presentation.